Nomura Holdings
RARE icon

Nomura Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Nomura Holdings’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,800
Closed -$896K – 2115
2025
Q3 		$896K Buy
29,800
+21,400
+255% +$642K ﹤0.01% 1431
2025
Q2 		$305K Buy
+8,400
New +$303K ﹤0.01% 1235

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Nomura Holdings's RARE Position: Q2 2026 in Review

Nomura Holdings sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 30,000 shares — an estimated $629K sold.

Nomura Holdings first reported a position in RARE in Q4 2019 and held it in 7 quarters. The position peaked at $13.2M in Q1 2023. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Nomura Holdings reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Nomura Holdings sold 30,000 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $629K.
  • Nomura Holdings first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 7 quarters.
  • Nomura Holdings's Ultragenyx Pharmaceutical position peaked at $13.2M in Q1 2023.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.